LL-37 (Cathelicidin Host Defence Peptide)

Also referred to as Cathelicidin antimicrobial peptide, hCAP-18 fragment.

Status: Investigational. LL-37 is not an FDA-approved drug product. It is an endogenous peptide, meaning the human body itself produces it, generated from the precursor protein hCAP-18 and studied extensively as part of innate immune host defence. Laboratory study of LL-37 does not translate into an approved therapeutic use, and its dual role in both defending against pathogens and, in some contexts, amplifying inflammatory or autoimmune signalling means it carries real theoretical risk alongside research interest.

LL-37 is the only cathelicidin-family antimicrobial peptide produced naturally by the human body, generated by immune cells and skin as part of innate host defence against microbes. It is studied extensively in laboratory settings for its antimicrobial and immune-modulating properties, but it is not an FDA-approved drug product, and no approved therapeutic version exists. Unlike many investigational peptides discussed for enhancement or recovery, LL-37 research carries a genuine two-sided profile: the same immune-activating signalling that makes it interesting also raises real theoretical concerns about excessive inflammation and autoimmune-like activity. This page focuses on explaining that duality rather than presenting LL-37 as a benign or emerging option.

What it is

LL-37 is a 37-amino-acid peptide, named for its first two residues (leucine-leucine) and its length, cleaved from a larger precursor protein called hCAP-18. It is naturally produced by neutrophils, skin cells, and other tissues as part of the body's own innate immune defence system, meaning it is endogenous rather than a synthetic invention. Research-grade LL-37 used in laboratories is synthesized to match this natural sequence for study purposes, not manufactured as a therapeutic drug.

Why people ask about it

Patients typically ask about LL-37 after reading about its role in fighting bacterial and fungal infections, or in the context of research on chronic inflammatory and autoimmune skin conditions like psoriasis, where LL-37 activity is abnormally elevated. Some encounter it through wound-healing or immune-support framing online without realizing the same peptide is implicated in worsening certain inflammatory skin diseases. That contradiction is exactly why a careful, unbiased explanation matters here.

Proposed mechanism

Laboratory research proposes that LL-37 works by directly disrupting microbial cell membranes, giving it broad antimicrobial activity against bacteria, fungi, and some viruses in cell-based assays. Separately, LL-37 has been proposed to act as an immune signalling molecule, binding to receptors on immune cells and amplifying inflammatory responses, including recruitment of additional immune cells to a site of infection or tissue damage. This same immune-amplifying activity has been proposed as a contributing mechanism in autoimmune and chronic inflammatory skin conditions when LL-37 is present at abnormally high levels or bound to self-DNA. These are laboratory-derived proposed mechanisms, and the balance between protective and harmful signalling in any individual person is not something that can currently be predicted or controlled.

What researchers have studied

• Cell-based antimicrobial activity against bacteria and fungi
• Role in innate immune defence at skin and mucosal barriers
• Involvement in psoriasis and other inflammatory skin disease models
• Interaction with self-DNA and autoimmune signalling pathways
• Wound-healing signalling in cell and animal models
• Structural studies of the peptide's membrane-disrupting activity

Human evidence

• LL-37 is naturally present in humans, and observational studies have measured its levels in conditions like psoriasis, rosacea, and infection, but this is correlational biomarker research rather than evidence of a therapeutic intervention.
• No controlled human trials evaluating administration of LL-37 as a treatment have been identified in the published literature.
• Elevated LL-37 activity has been observed in inflammatory skin disease in humans, which points toward risk from excess or dysregulated signalling rather than a demonstrated benefit from supplementation.
• Because LL-37 already exists naturally in the body, distinguishing any effect of external administration from normal physiological variation would require carefully controlled human studies that do not yet exist.

Preclinical evidence

• Cell-based assays have reported direct antimicrobial activity against a range of bacterial and fungal species.
• Animal models have reported involvement of LL-37 in wound-healing signalling processes.
• Laboratory studies have reported that LL-37 bound to self-DNA can activate immune pathways associated with autoimmune-like inflammation.
• Cell and animal models of psoriasis have reported that excess LL-37 signalling contributes to inflammatory disease processes.
• These findings describe laboratory and animal observations of a naturally occurring peptide and do not constitute evidence for any therapeutic administration in humans.

What is not yet known

• Whether externally administered LL-37 could be given to humans without triggering the same inflammatory or autoimmune-like signalling observed with naturally elevated levels.
• Any exposure range that would favor antimicrobial benefit over inflammatory risk in a given person.
• Long-term safety of altering levels of an endogenous immune peptide from outside the body.
• How individual variation in baseline immune activity would affect any response to added LL-37.
• The purity, identity, and consistency of unregulated research-grade products sold under this name.
• Whether any legitimate therapeutic pathway for LL-37 will emerge given its dual protective and inflammatory roles.

Regulatory status and access

LL-37 is not available as an individually prescribable product; it appears here strictly as a subject of laboratory and translational research rather than a substance offered to patients. Compounding elsewhere is never the same as FDA approval. Ask about current availability. A physician determines medical appropriateness only after a full evaluation.

Known and potential risks

• Real theoretical risk of amplifying inflammatory or autoimmune-like signalling, since this same peptide is implicated in worsening conditions like psoriasis when present at elevated levels.
• No established human safety profile exists for externally administered LL-37 at any exposure level.
• Unregulated research-market products carry uncertainty about purity, identity, and sterility.
• The body's own regulation of this peptide is complex, and externally adding to it could unpredictably shift a person's natural inflammatory balance.
• Interaction with existing autoimmune or inflammatory skin conditions is unstudied and could plausibly worsen disease activity.
• Marketing language framing LL-37 as a simple immune booster ignores its documented role in inflammatory disease and should be treated with caution.

Cautions and who may not be a candidate

• Any diagnosed autoimmune or chronic inflammatory skin condition, including psoriasis and rosacea, given LL-37's documented role in those disease processes.
• Pregnancy and breastfeeding, given the absence of human safety data.
• Active infection or immunocompromised states without physician coordination.
• Active or suspected malignancy, given unresolved questions about immune pathway modulation.
• Known hypersensitivity to peptide compounds generally.
• Use as a substitute for an evaluated, evidence-based approach to an infectious or inflammatory condition.

Questions to discuss with a physician

• Given that LL-37 is linked to worsening inflammatory skin disease, why would anyone consider adding more of it?
• How does the body naturally regulate this peptide, and what happens when that regulation is disrupted?
• What established immune-support or antimicrobial options have stronger human evidence?
• How would my existing skin or autoimmune history change the risk profile here?
• What symptoms would mean I should stop and seek care immediately?
• Is there a legitimate research pathway through which LL-37 could ever have a defined therapeutic role?

Frequently asked questions

Is LL-37 FDA-approved?

No. LL-37 is not an FDA-approved drug product for any indication. It is a naturally occurring immune peptide studied in laboratory research, not an approved therapeutic.

Does GOAL.MD sell LL-37?

This page is educational only and does not describe a product for sale. Ask about current availability, and appropriateness is determined only by a physician after evaluation.

Is LL-37 naturally found in the human body?

Yes. LL-37 is an endogenous peptide produced by immune cells and skin as part of the body's own innate host defence system; it is not a synthetic invention.

Can LL-37 make inflammation worse?

Research has linked abnormally elevated LL-37 activity to inflammatory skin conditions like psoriasis, so this is a real theoretical risk rather than a purely hypothetical concern.

Has LL-37 been given to people as a treatment?

No controlled human trials evaluating LL-37 administration as a treatment have been identified. Human data are limited to observational measurements of naturally occurring levels in disease states.

What has LL-37 been studied for?

Laboratory research has focused on its antimicrobial activity against bacteria and fungi, its role in innate immune defence, and its involvement in inflammatory skin disease.

Is LL-37 safe to take externally?

No established human safety profile exists for external administration, and its documented role in inflammatory disease means added exposure carries real, unresolved risk.

Should someone with psoriasis or an autoimmune condition consider LL-37?

This should be avoided outside of research contexts and discussed with a physician, since LL-37 is specifically implicated in worsening these types of inflammatory processes.

Can a doctor prescribe LL-37?

It is not offered as a standalone prescription product. A physician can explain the research and why its dual immune role makes it different from most other investigational peptides discussed online.

What is LL-37?

LL-37 is a 37-amino-acid peptide, named for its first two residues (leucine-leucine) and its length, cleaved from a larger precursor protein called hCAP-18. It is naturally produced by neutrophils, skin cells, and other tissues as part of the body's own innate immune defence system, meaning it is endogenous rather than a synthetic invention. Research-grade LL-37 used in laboratories is synthesized to match this natural sequence for study purposes, not manufactured as a therapeutic drug.

Does the legal or regulatory status of LL-37 tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare LL-37?

LL-37 is not available as an individually prescribable product; it appears here strictly as a subject of laboratory and translational research rather than a substance offered to patients. Compounding elsewhere is never the same as FDA approval.

What human evidence exists for LL-37?

Human information is limited to case reports or uncontrolled observations, which cannot establish benefit. LL-37 is naturally present in humans, and observational studies have measured its levels in conditions like psoriasis, rosacea, and infection, but this is correlational biomarker research rather than evidence of a therapeutic intervention.

Have there been controlled human trials of LL-37?

Published human information is limited to case-level or uncontrolled observation rather than controlled trials, so benefit has not been established.

What do case reports about LL-37 actually show?

Case-level reports describe what happened to specific people without a comparison group. They can raise a question worth studying, and they cannot show that an effect was caused by the substance. No controlled human trials evaluating administration of LL-37 as a treatment have been identified in the published literature.

What have animal and laboratory studies of LL-37 reported?

Cell-based assays have reported direct antimicrobial activity against a range of bacterial and fungal species; Animal models have reported involvement of LL-37 in wound-healing signalling processes; Laboratory studies have reported that LL-37 bound to self-DNA can activate immune pathways associated with autoimmune-like inflammation. These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for LL-37 mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is LL-37 proposed to work?

Laboratory research proposes that LL-37 works by directly disrupting microbial cell membranes, giving it broad antimicrobial activity against bacteria, fungi, and some viruses in cell-based assays. Separately, LL-37 has been proposed to act as an immune signalling molecule, binding to receptors on immune cells and amplifying inflammatory responses, including recruitment of additional immune cells to a site of infection or tissue damage. This is a proposed pathway rather than a demonstrated effect.

What is LL-37 being studied for?

Published work has focused on Cell-based antimicrobial activity against bacteria and fungi; Role in innate immune defence at skin and mucosal barriers; Involvement in psoriasis and other inflammatory skin disease models; Interaction with self-DNA and autoimmune signalling pathways. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about LL-37?

Whether externally administered LL-37 could be given to humans without triggering the same inflammatory or autoimmune-like signalling observed with naturally elevated levels; Any exposure range that would favor antimicrobial benefit over inflammatory risk in a given person; Long-term safety of altering levels of an endogenous immune peptide from outside the body; How individual variation in baseline immune activity would affect any response to added LL-37.

What are the risks of LL-37?

Real theoretical risk of amplifying inflammatory or autoimmune-like signalling, since this same peptide is implicated in worsening conditions like psoriasis when present at elevated levels; No established human safety profile exists for externally administered LL-37 at any exposure level; Unregulated research-market products carry uncertainty about purity, identity, and sterility.

Who should not consider LL-37?

A physician would generally consider it inappropriate in these situations without specialist input: Any diagnosed autoimmune or chronic inflammatory skin condition, including psoriasis and rosacea, given LL-37's documented role in those disease processes; Pregnancy and breastfeeding, given the absence of human safety data; Active infection or immunocompromised states without physician coordination; Active or suspected malignancy, given unresolved questions about immune pathway modulation.

Is LL-37 appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

How does LL-37 interact with other medications?

Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Interaction with existing autoimmune or inflammatory skin conditions is unstudied and could plausibly worsen disease activity.

What would a physician monitor if LL-37 were discussed?

Monitoring concepts include Baseline evaluation of any existing inflammatory, autoimmune, or dermatologic condition; Coordination with a dermatology or immunology care team where relevant history exists; Ongoing clinical reassessment for signs of new or worsening inflammatory activity. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as LL-37 verified?

No. Unregulated research-market products carry uncertainty about purity, identity, and sterility. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about LL-37?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about LL-37?

Useful questions include: Given that LL-37 is linked to worsening inflammatory skin disease, why would anyone consider adding more of it?; How does the body naturally regulate this peptide, and what happens when that regulation is disrupted?; What established immune-support or antimicrobial options have stronger human evidence?; How would my existing skin or autoimmune history change the risk profile here?.

Why do people ask about LL-37?

Patients typically ask about LL-37 after reading about its role in fighting bacterial and fungal infections, or in the context of research on chronic inflammatory and autoimmune skin conditions like psoriasis, where LL-37 activity is abnormally elevated. Some encounter it through wound-healing or immune-support framing online without realizing the same peptide is implicated in worsening certain inflammatory skin diseases.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.